Pharmacokinetics and Dose Optimization Strategies of Para-Aminosalicylic Acid in Children with Rifampicin-Resistant Tuberculosis

Treatment options for children with Rifampicin-resistant tuberculosis (RR-TB) remain limited, and para-aminosalicylic acid (PAS) is still a relevant component of treatment regimens. Prevention of resistance to companion drugs by PAS is dose related, and at higher concentrations, PAS may exhibit sign...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Antimicrobial agents and chemotherapy Ročník 66; číslo 6; s. e0226421
Hlavní autoři:	van der Laan, Louvina E, Garcia-Prats, Anthony J, Schaaf, H Simon, Chirehwa, Maxwell, Winckler, Jana L, Mao, Jun, Draper, Heather R, Wiesner, Lubbe, Norman, Jennifer, McIlleron, Helen, Donald, Peter R, Hesseling, Anneke C, Denti, Paolo
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 21.06.2022
Témata:	Adult Aminosalicylic Acid - pharmacokinetics Aminosalicylic Acid - therapeutic use Antitubercular Agents - pharmacokinetics Antitubercular Agents - therapeutic use Child Drug Administration Schedule HIV Infections - drug therapy Humans Rifampin - pharmacokinetics Rifampin - therapeutic use Tuberculosis, Multidrug-Resistant - drug therapy second-line treatment para-aminosalicylic acid Mycobacterium tuberculosis pediatrics clinical pharmacology Rifampicin-resistant tuberculosis population pharmacokinetics
ISSN:	1098-6596, 1098-6596
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!